What are Mission Vision & Core Values of BICO Company?

How does BICO define its purpose and future direction?

BICO’s mission, vision and values unify its bio-convergence activities, guiding R&D, capital allocation and partnerships across 3D bioprinting, cell therapy tools and lab automation. These principles help align global teams and investors toward measurable impact.

BICO’s strategic statements anchor decision-making in a market surpassing $120 billion (2025), ensuring technology development and commercialisation stay cohesive amid rapid disruption. BICO Porter's Five Forces Analysis

BICO’s mission is to create the future of health by converging biology and engineering, accelerating drug discovery and regenerative medicine with bio-convergent platforms for researchers and industry worldwide.

Bio‑convergence

Integrating hardware, software and biology to enable predictable human tissue models.

Customer focus

Serving academic labs, biotechs and pharma with scalable, automated workflows.

Innovation

Product development like the BIO X6 bioprinter demonstrates multi‑bioink, multi‑material capability.

Automation

Combining single‑cell isolation and precision liquid handling to speed drug screening pipelines.

Platform provider

Moving beyond equipment sales to offer integrated platforms for personalized medicine development.

Global impact

Targeting a global market; in 2024 BICO reported revenue growth reflecting expansion in life‑science tooling.

BICO’s mission centers on bio‑convergence to enable predictable biology and faster therapeutics development for global research and industry partners.

Competitors Landscape of BICO

Complete BICO Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

BICO Company Vision: To eliminate organ shortages and speed drug development through scalable biofabrication, while achieving operational excellence and profitability by mid-2025.

Moonshot Purpose

To phase from models to transplantable tissues, targeting clinical-scale organs in the 2030s while today enabling safer drug testing.

Commercial Traction

By 2025 BICO shifted to profitability focus, improving margins while maintaining R&D investment in bioprinting platforms.

Market Leadership

Holds a significant share of the global installed base for bioprinters and related lab automation used in toxicity testing.

Near-Term Impact

Current 3D-printed skin and liver models reduce animal testing and accelerate preclinical workflows for pharma partners.

Strategic North Star

The vision guides hiring, partnerships, and product roadmaps to balance commercial returns with long-term clinical goals.

Evidence-Based Steps

Incremental milestones: widespread adoption of tissue models for toxicity testing, scaled manufacturing of bioinks, and regulatory collaborations.

To reduce the organ shortage and accelerate drug development by scaling biofabrication from validated tissue models to clinical-grade organs, while sustaining commercial performance and R&D investment.

Related reading: Brief History of BICO

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

BICO Company core values guide decisions, culture and product development, blending biotech rigor with startup speed; they shape how the company pursues innovation, integrity and operational excellence across R&D and commercial activities.

Dare to be different — encourages bold experimentation and accessible bioprinting; Passion — drives deep customer collaboration and high R&D reinvestment; Integrity — ensures reproducible data, ethical conduct and transparent investor communication; Excellence — focuses on precision manufacturing and reliable automated workflows.

Dare to be different

Encourages challenging norms and pursuing unconventional scientific solutions; exemplified by early moves to democratize bioprinting and disrupt high-cost barriers.

Passion

Drives commitment to improving health outcomes through close customer collaboration and sustained R&D reinvestment, supporting transformative product development.

Integrity

Prioritizes data accuracy, ethical conduct and transparent reporting; reflected in rigorous quality control for reagents and public updates on the 2024–2025 shift toward cash-flow-positive operations.

Excellence

Centers on precision and high performance via the BICO Excellence System, optimizing manufacturing and achieving nanoliter-scale liquid handling accuracy in 2025.

Explore how these BICO Company Mission and BICO Company Vision statements shape strategic decisions and growth — read the next chapter: Mission, Vision & Core Values of BICO

BICO Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Mission and vision statements shape strategic choices by prioritizing long-term investments and guiding portfolio focus. They inform capital allocation, partnerships, product roadmaps and market expansion decisions across the organization.

BICO Company Mission, Vision & Core Values

Clear guiding statements align R&D, commercial strategy and M&A to advance bio-convergence and scalable health solutions.

• BICO Company Mission: converge biology and engineering to enable scalable life-science workflows and therapeutic solutions
• BICO Company Vision: lead bio-convergence to accelerate adoption of bioprinting, lab automation and translational tools globally
• BICO Core Values: scientific rigor, innovation, customer-centricity and collaborative partnerships
• Strategic impact: mission-driven prioritization of high-margin automation and consumables

Mission in Practice

The mission steers product roadmaps toward integrated platforms that scale research to application, emphasizing reproducibility and throughput.

Vision-Led Growth

The vision targets global leadership in bio-convergence, driving expansion in the U.S. and Asia-Pacific with demonstration centers and commercial hubs.

Values Driving Decisions

Core values inform hiring, partnerships and ethical frameworks, ensuring alignment across acquisitions and internal initiatives.

Strategic Pivot 2024–2025

Company shifted from acquisition-led 'Buy and Build' to 'Focus and Optimize', prioritizing high-margin lab automation and bioprinting consumables.

Partnerships & Research

Collaborations such as with Wake Forest Institute for Regenerative Medicine advance tissue-engineering objectives and translational outcomes.

KPIs and Measurement

Leadership ties strategy to KPIs including 15-20% organic growth targets in core segments and over 2,500 publications using company technologies by mid-2025.

Mission and vision influence product focus, partnerships and regional expansion; read the next chapter on Core Improvements to Company's Mission and Vision to see proposed updates and tactical changes.

Influence: The mission and vision statements drove the 2024–2025 pivot from acquisition-heavy growth to prioritizing high-margin laboratory automation and bioprinting consumables, aligning with the goal of converging biology and engineering. Partnerships like Wake Forest support the tissue-engineering vision. Market expansion in the U.S. and Asia-Pacific included 'Bio-convergence Centers' to showcase integrated workflows. Leadership cites these principles on earnings calls to justify AI-driven drug discovery investments. Targets include 15-20% organic growth in key segments and > 2,500 peer-reviewed publications by mid-2025, showing the statements are embedded in KPIs. Read more on commercial and financial structure in Revenue Streams & Business Model of BICO

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE

BICO’s mission and vision can be made more robust by embedding explicit ethical, regulatory and sustainability commitments to match rapid advances in bio-convergence. Four targeted improvements focus on clarifying responsibility, sustainability, AI integration, and investor-aligned reliability.

Embed explicit ethical and regulatory duties

Revise the BICO Company mission to include 'safe, ethical, and accessible convergence' to signal commitment to clinical-grade standards and regulatory compliance as bioprinting approaches human trials.

Introduce a measurable sustainability target

Add a vision goal such as leading the transition to animal-free drug testing by 2030, aligning BICO Company Vision with policy shifts and consumer preferences on animal welfare.

Highlight AI and data-driven biological modelling

Update the mission to reflect integration of artificial intelligence for predictive biological models, positioning BICO Company Mission to capture data-science led product differentiation.

Balance disruption with long-term reliability

Incorporate language that reassures institutional investors on sustainability and reliability to complement the disruptive positioning found in current BICO Company values statement.

Improvements

BICO’s mission and vision could be strengthened by explicitly incorporating the ethical and regulatory responsibilities inherent in advanced biotechnologies; as the industry moves closer to clinical trials for bio-printed tissues, a mission statement that includes 'safe, ethical, and accessible convergence' would align better with global healthcare standards. Compared to established competitors like Sartorius, BICO’s statements are highly focused on disruption, which can sometimes overshadow the importance of long-term sustainability and reliability in the eyes of more conservative institutional investors.

A specific refinement would be to integrate a sustainability goal into the vision, such as 'leading the transition to animal-free drug testing by 2030,' aligning with evolving consumer behaviors and tightening regulations regarding animal welfare in research. Additionally, as data science becomes a larger part of the bio-convergence equation, the mission could be updated to reflect the role of artificial intelligence in biological modeling.

Framing these as growth opportunities, BICO can leverage its position to set the standard for ESG excellence in the bioprinting industry; BICO reported pro forma revenue of approximately SEK 2.1 billion in 2024 and R&D investment representing roughly 18% of revenue, indicators that support investment in ethical, sustainable, and AI-driven mission refinements. For context on market positioning and target segments see Target Market of BICO.

Keywords: BICO Company Mission, BICO Company Vision, BICO Core Values, BICO Company values statement, What is BICO Company's mission, BICO organizational principles, BICO Company mission statement explained, Where to find BICO Company core values, BICO Company vision and mission comparison, What are the guiding principles of BICO Company, BICO Company values and culture, How does BICO Company define its vision, Detailed explanation of BICO Company core values, BICO Company purpose and values, BICO Company strategic direction mission vision, Latest BICO Company mission and values update, BICO Company leadership values, What is the purpose of BICO Company, BICO Company ethical framework core values, Searching for BICO Company mission statement PDF, BICO Company commitment and values